Analyst Price Targets — RVTY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 3, 2026 3:05 pm | Catherine Ramsey Schulte | Robert W. Baird | $129.00 | $103.89 | TheFly | Revvity price target raised to $129 from $123 at Baird |
| February 3, 2026 1:10 pm | — | Cowen & Co. | $124.00 | $106.97 | TheFly | Revvity price target raised to $124 from $120 at TD Cowen |
| February 3, 2026 12:55 pm | — | Evercore ISI | $118.00 | $107.09 | TheFly | Revvity price target raised to $118 from $112 at Evercore ISI |
| February 3, 2026 10:28 am | — | Barclays | $118.00 | $107.09 | TheFly | Revvity price target raised to $118 from $115 at Barclays |
| February 2, 2026 7:27 pm | — | Jefferies | $105.00 | $107.05 | TheFly | Revvity price target raised to $105 from $100 at Jefferies |
| December 15, 2025 11:29 am | Brandon Couillard | Wells Fargo | $107.00 | $100.46 | TheFly | Revvity price target raised to $107 from $102 at Wells Fargo |
| December 15, 2025 10:56 am | Luke Sergott | Barclays | $115.00 | $100.46 | TheFly | Revvity price target raised to $115 from $105 at Barclays |
| December 9, 2025 9:28 am | Evie Koslosky | Goldman Sachs | $105.00 | $99.79 | TheFly | Revvity initiated with a Neutral at Goldman Sachs |
| October 28, 2025 11:19 am | — | Robert W. Baird | $123.00 | $97.74 | TheFly | Revvity price target raised to $123 from $122 at Baird |
| October 28, 2025 9:16 am | — | Barclays | $105.00 | $97.16 | TheFly | Revvity price target raised to $105 from $100 at Barclays |
Latest News for RVTY
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday, March 2, 2026 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 46th Annual Health Care Conference Tuesday, March 3, 2026 2:30 p.m. ET - Prahlad Singh, president and chief…
WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the…
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RVTY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.